Gentian Diagnostics ASA ( (DE:6FK) ) has provided an announcement.
Gentian Diagnostics has launched the GCAL® Calprotectin Immunoassay in collaboration with Beckman Coulter Diagnostics. This partnership aims to enhance diagnostic efficiency by providing precise measurement of calprotectin, a key biomarker for inflammation. The collaboration marks a significant milestone for Gentian, leveraging Beckman Coulter’s expertise to improve diagnostic tools and patient outcomes, thereby strengthening Gentian’s market position in clinical diagnostics.
More about Gentian Diagnostics ASA
Gentian Diagnostics, headquartered in Moss, Norway, develops and manufactures high-quality in vitro diagnostic reagents. The company specializes in homogenous immunoassays for infections, inflammations, kidney failures, and congestive heart failures. By automating clinically relevant biomarkers, Gentian aims to reduce costs and improve patient care. It serves global human and veterinary diagnostics markets through offices in Sweden, USA, and China.
YTD Price Performance: 24.38%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €61.33M
Find detailed analytics on 6FK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com